Eckert & Ziegler Exceeds its Revenue Expectations

(Ad hoc-Mitteilung)

Berlin, 10.01.2001. Eckert & Ziegler Strahlen- und Medizintechnik AG (WKN 565 970), a leading manufacturer of innovative treatments against cancer and cardiological diseases. Preliminary estimates show increased revenues by 130% to 23 Mio EURO (9,9 Mio EURO) in the fiscal year 2000. The Berlin medical device company has clearly exceeded its revenue expectations and continues its extraordinary growth. The jump in revenue is primarily driven from the USA due to the increa- sing business in nuclear medicine reference sources and standards. The final numbers for the fiscal year 2000 will be published on March 29, 2001.

The Board of Directors